SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

CORRECTION: Stemline Therapeutics Sees Q4 Sees Prelim. Q4 Net Revenues For ELZONRIS $11.8M; A Prior Headline Indicated This Was The FY19 Estimate, This Was Incorrect

Benzinga · -